The abstract is read at the publisher; the summary is JClub's.
In the LATTICE randomized trial of 80 older adults with mild cognitive impairment, plasma GDF15 most consistently tracked CDR Sum of Boxes change and modified low-dose lithium effects in the amnestic subgroup.
- Why it matters: Lithium’s neuroprotective mechanisms in Alzheimer disease–relevant states are not well defined, and biomarkers are needed to link amyloid pathology, progression, and treatment response.
- What they did: Longitudinal plasma from participants randomized to low-dose lithium carbonate or placebo for 2 years was profiled with the NULISAseq CNS Disease Panel 120, testing baseline protein links to amyloid beta PET and subsequent cognitive, functional, and neuroimaging trajectories.
- The result: GDF15 associations with CDR Sum of Boxes trajectories and lithium treatment-effect modification remained significant after false discovery rate correction in amnestic MCI, while p-tau217 most consistently related to hippocampal volume trajectories.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.